Published in final edited form as:

Cell Mol Life Sci. 2015 July ; 72(13): 2461–2473. doi:10.1007/s00018-015-1835-0.

Molecular Mechanisms of CD8⁺ T cell Trafficking and Localization

Jeffrey C. Nolz^{1,2,3,4}

¹Department of Molecular Microbiology and Immunology Oregon Health and Science University, Portland, OR 97239

²Department of Cell, Developmental, and Cancer Biology Oregon Health and Science University, Portland, OR 97239

³Department of Radiation Medicine Oregon Health and Science University, Portland, OR 97239

Abstract

Cytotoxic CD8⁺ T cells are potent mediators of host protection against disease due to their ability to directly kill cells infected with intracellular pathogens and produce inflammatory cytokines at the site of infection. To fully achieve this objective, naïve CD8⁺ T cells must be able to survey the entire body for the presence of foreign or “non-self” antigen that is delivered to draining lymph nodes following infection or tissue injury. Once activated, CD8⁺ T cells undergo many rounds of cell division, acquire effector functions, and are no longer restricted to the circulation and lymphoid compartments like their naïve counterparts, but rather are drawn to inflamed tissues in order to combat infection. As CD8⁺ T cells transition from naïve to effector to memory populations, this is accompanied by dynamic changes in the expression of adhesion molecules and chemokine receptors that ultimately dictate their localization *in vivo*. Thus, an understanding of the molecular mechanisms regulating CD8⁺ T cell trafficking and localization are critical for vaccine design, control of infectious diseases, treatment of autoimmune disorders, and cancer immunotherapy.

Keywords

CD8⁺ T cells; Selectins; Integrins; Chemokines; Vaccines; Trafficking

INTRODUCTION

Antigen-specific CD8⁺ T cells have the ability to recognize and destroy cells infected with intracellular pathogens [1,2]. Prior to acquiring this type of effector function, a previously naïve CD8⁺ T cell needs to become activated through the recognition of cognate antigen presented on major histocompatibility complex-I (MHC-I) by antigen presenting cells (APCs), which typically occurs in secondary lymphoid organs. These activated CD8⁺ T cells must then find and successfully enter infected tissues in order to contribute to host

⁴Corresponding Author: Jeffrey C. Nolz, PhD 6516 Richard Jones Hall 3181 SW Sam Jackson Park Road Mail Code: L220 Portland, OR 97239 503-494-1356 nolz@ohsu.edu.

protection. Because recently activated CD8⁺ T cells will subsequently differentiate into a long-lived memory population, the mechanisms controlling CD8⁺ T cell trafficking and localization are critically important considerations for vaccine design against a variety of pathogens [3-5]. In addition, a number of experimental models and ever growing clinical evidence has suggested that both activation and localization of CD8⁺ T cells is critical for successful tumor immunotherapy [6]. In fact, the localization and subsequent infiltration of CD8⁺ T cells into tumors is a key factor that predicts clinical outcome in cancer patients [7,8]. Thus, a comprehensive understanding of the mechanisms that ultimately regulate the trafficking and localization of CD8⁺ T cells *in vivo* has broad implications as it relates to human disease.

Within the human CD8⁺ T cell repertoire, there exists a continuum of diversity ranging from antigen-naïve cells to more terminally differentiated antigen-experienced subsets [9]. This diversity is generated over time in response to a variety of environmental factors and antigens and, theoretically, functions to optimize host protection against pathogens, while limiting severe immunopathology during tissue injury or infection. In fact, memory CD8⁺ T cells that are specific for different viruses often exhibit diverse, virus-specific phenotypes [10-13]. This suggests that CD8⁺ T cells that respond to any particular pathogen or environmental antigen undergo specific differentiation resulting in extensive heterogeneity within the CD8⁺ T cell compartment. Besides exhibiting several diverse functional differences, these heterogeneous populations of CD8⁺ T cells also likely exhibit unique trafficking patterns that ultimately contribute to their function *in vivo*.

In general, the trafficking and localization of all leukocyte populations is regulated through the collective integration of selectin, chemokine receptor, and integrin interactions [14]. Importantly, although both CD4⁺ and CD8⁺ T cells express many of the same receptors and ligands that influence trafficking and localization, it should not be always assumed that the molecular mechanisms identified that regulate trafficking and localization of one of these cell types is necessarily interchangeable with the other [15]. During homeostatic, steady-state conditions, most CD8⁺ T cells freely distribute between the circulation and secondary lymphoid organs [16]. However, following infection or inflammatory-related injury, the trafficking patterns of CD8⁺ T cells change dramatically, through the collective actions of antigen and inflammatory cytokines that impact the expression of homing molecules both on the T cells as well as the vasculature. In many instances, lack of expression (or artificially interfering with the binding) of a single adhesion or chemokine receptor can often result in a profound defect in the trafficking of a CD8⁺ T cell population to a specific tissue and prevent pathogen clearance. Because of the critical role CD8⁺ T cells play in eliminating infected or malignant cells from the body, this review focuses on the molecular mechanisms that regulate the trafficking and localization of this specific cell population.

TRAFFICKING OF NAÏVE CD8⁺ T CELLS

Following successful positive selection and exit of the thymus, mature, but antigen inexperienced CD8⁺ T will enter the circulation and remain in a naïve state until efficiently stimulated by cognate antigen. Because any particular antigen-specific CD8⁺ T cell is present at very rare frequencies in a naïve repertoire [17,18], these cells must be able to

rapidly and completely survey all areas of the body in order to increase the likelihood of coming in contact with their cognate antigen. In order to accomplish this, naïve T cells utilize the circulatory system to travel to and survey the many lymph nodes dispersed throughout the body and will also enter the white pulp of the spleen. As naïve CD8⁺ T cells passively transit within the vasculature they will subsequently be drawn directly into lymph nodes by extravasating across High Endothelial Venules (HEVs) [19]. Following a phase of scanning the lymph node for antigen, the naïve CD8⁺ T cell will exit the lymph node, enter the efferent lymphatic vessels, and then return to the blood stream via the thoracic duct or right lymphatic duct [20]. In general, naïve CD8⁺ T cells will follow this unidirectional trafficking pattern until stimulated by mature dendritic cells presenting antigenic peptide, resulting in T cell activation.

Signaling Cascade for Entering Lymph Nodes

As mentioned previously, naïve CD8⁺ T cells are restricted to the circulation, lymph nodes, lymph, and white pulp of the spleen. The molecular requirement for the entry of naïve CD8⁺ T cells into lymph nodes has been extensively studied and collectively these findings reveal a model where three critical receptor – ligand interactions are required for sufficient entry of naïve CD8⁺ T cells across HEVs (Figure 1). HEVs are specialized blood vessels that are decorated with the combination of adhesion molecules and chemokines that efficiently recruits naïve CD8⁺ T cells directly into the lymph node from the circulation during homeostatic conditions. Specifically, HEVs express Peripheral Node Addressins (PNAd), a group of mucin-like adhesion molecules that are defined by reacting with the monoclonal antibody MECA-79, which serve as ligands for L-selectin (CD62L) [21]. Specifically, MECA-79 detects expression of 6-sulfo-sialyl-Lewis X motifs on core 1 O-glycans and this carbohydrate motif can be found on a variety of sialomucin proteins such as CD34, glycosylation-dependent cell adhesion molecule-1 (GlyCAM-1), endomucin and nepmucin [22,23]. This carbohydrate motif is not necessarily restricted to core 1 O-glycans and is also generated on both core 2 O-glycans and N-glycans [24] (Figure 2). CD62L is expressed by all naïve CD8⁺ T cells and mediates the initial interaction between the cell and the surface of the HEV (Figure 1). Interestingly, activated platelets have also been shown to contribute to T cell interactions with PNAd on HEVs and can regulate lymph node homing in the absence of CD62L [25,26]. Once selectin-mediated rolling on PNAd occurs, this brings the naïve CD8⁺ T cell into close proximity of the HEV to allow subsequent stimulation of the chemokine receptor CCR7 with chemokines that are presented by the endothelium.

Chemokines are a family of small, structurally related proteins that bind to seven transmembrane G-protein coupled receptors and are critical regulators of leukocyte extravasation and migration [27,28]. The binding of a chemokine to its specific chemokine receptor(s) causes GDP to GTP exchange on the G α subunit of the associated heterotrimeric (G $\alpha\beta\gamma$) complex. GDP to GTP exchange causes dissociation of the complex into the G α and G $\beta\gamma$ subunits that initiate downstream signaling including the activation of Rho GTPases and mobilization of calcium, resulting in cellular polarization, reorganization of the actin cytoskeleton, activation of cell surface integrins, and ultimately, cell migration [29]. Chemokines can be broadly defined as being either ‘homeostatic’ or ‘inflammatory’ depending on whether they are present during the steady-state or following infection,

respectively. Such homeostatic chemokines include those that regulate hematopoiesis, thymocyte development, and the recruitment of naïve T cells into and within lymph nodes. Both CCL19 and CCL21 are homeostatic chemokines and ligands for CCR7 [30], although CCL21 appears to be the dominant chemokine regulating naïve CD8⁺ T cell recruitment across HEV's in mice, whereas CCL19 may also be expressed on HEV's in humans [31]. Endothelial cells of the HEV constitutively present luminal CCL21 on heparan sulfate [32] to stimulate CCR7-mediated integrin activation on circulating naïve CD8⁺ T cells, resulting in firm adhesion of the T cell to the HEV.

Integrins are a diverse family of heterodimeric cell surface receptors and the collective combination of an integrin α and β chain determines its specificity toward a variety of ligands. Activation of cell surface integrins occurs through a process known as “inside-out signaling”, whereas signaling pathways from within the cell drive both integrin clustering and affinity maturation, resulting in an increased ability for the integrin to bind ligand [33]. In the case of naïve CD8⁺ T cell extravasation into lymph nodes, signaling through CCR7 provides the “inside-out” signal for subsequent activation of the $\alpha_L\beta_2$ integrin (CD11a/CD18), Leukocyte Functional Antigen-1 (LFA-1) and allows it to bind to its ligands intracellular adhesion molecule-1 (ICAM-1) and ICAM-2 [34]. In fact, genetically forced high affinity status of LFA-1 results in adhesion of naïve T cells to HEVs without the need for chemokine signaling [35]. Following LFA-1-mediated firm adhesion to the HEV, naïve CD8⁺ T cells will subsequently scan the endothelium until they find an “entry point” and complete the extravasation process (Figure 1).

Migration Within Lymph Nodes

Lymph nodes are specialized, compartmentalized structures that function as a crossroad between innate and adaptive immunity. It is here that professional APCs known as dendritic cells, which have migrated from tissues to the draining lymph node via the afferent lymph, allow naïve T cells to scan them for the presence of cognate antigen. Interestingly, the continual migration of CD11c⁺ dendritic cells to the draining lymph node also contributes the overall integrity of HEVs [36]. Specifically, lymphotoxins (lymphotoxin α , lymphotoxin β and LIGHT) produced by these dendritic cells act directly on the HEV to maintain ligands for CD62L, which is required for the efficient recruitment of naïve CD8⁺ T cells into the lymph node. Once a naïve CD8⁺ T cell crosses the HEV, it will continue to migrate within the paracortex region of the lymph node, in contrast to B cells, which migrate to the follicles [37]. Recent studies using intravital microscopy have begun to characterize the mechanisms that regulate the migration patterns of naïve CD8⁺ T cell populations within the lymph node, as well as the interactions that occur between naïve CD8⁺ T cells and activated dendritic cells following infection.

Naïve CD8⁺ T cells again primarily utilize CCR7 to navigate throughout the paracortex of the lymph node, although it is clear that additional G-protein coupled receptors are also involved [38,39]. Here, a network of fibroblastic reticular cells (FRCs) form the navigation grid for naïve T cells to randomly scan the dendritic cells that have migrated into these T cell zones [40,41]. Fibroblastic reticular cells produce the homeostatic chemokines CCL19 and CCL21, thus providing the ligands for CCR7-expressing naïve CD8⁺ T cells to follow

across this cellular network and retain these cells within the lymph node. Not only do these chemokines facilitate the migration pattern of naïve T cells, but it is also believed that the expression pattern of these chemokines orchestrates the compartmentalization of the lymph node into the T and B cell zones. There is also evidence that activated CD4⁺ T cells can recruit naïve CD8⁺ T cells toward antigen-presenting dendritic cells in the lymph node through the localized production of the chemokines CCL3 and CCL4 [42].

Interaction of naïve CD8⁺ T cells with dendritic cells occurs following recognition of cognate antigen and results in stable conjugation between these two cell types. Initially, a naïve antigen-specific CD8⁺ T cells will make brief, serial contacts with a dendritic cell before making a stable conjugate, a process that is influenced by both the affinity and quantity of antigen [43-45]. Here, stimulation of the T cell receptor (TCR) with peptide-MHC-I provides the “inside-out signal” needed for stable conjugation between the two cell types mediated by the integrin LFA-1 on the T cell and ICAM on the dendritic cell [46,47]. Early studies suggested that these conjugations formed primarily in the T cell zone of the lymph node. However, more recent studies suggest that following a viral or parasitic infection, dendritic cell priming of T cells occurs in the subcapsular sinus region or interfollicular region of the lymph node [48,49]. Thus, where CD8⁺ T cell activation occurs in the lymph node appears to be regulated by the location of antigen bearing dendritic cells and may vary based on the type of infection or vaccination.

Regulation of Lymph Node Egress

A naïve CD8⁺ T cell will spend approximately 12-24 hours in a given lymph node before it enters the draining lymphatics and returns to the circulation [50,51]. Egress of CD8⁺ T cells from lymph nodes is under the control of a naturally occurring gradient of sphingosine-1 phosphate (S1P) and its receptor S1PR1 (also known as S1P₁) expressed on the CD8⁺ T cell [52]. This gradient is generated through a combination of sphingosine kinases and lyases, which results in high expression of sphingosine-1 phosphate in the blood and lymph, but lower levels inside the lymph node [53]. Like chemokine receptors, S1PR1 is a G-protein coupled receptor and its signaling causes polarization and migration of T cells toward higher concentrations of ligand. Binding of S1P to S1PR1 results in rapid internalization and degradation of the receptor, and as such, expression of S1PR1 is found on naïve CD8⁺ T cells in the lymph node, but not in the blood or lymph. The immunosuppressive drug FTY720 is a functional antagonist of S1PR1 and treatment results in sequestration of CD8⁺ T cells in lymph nodes [54]. Thus, the retention time of CD8⁺ T cells in lymph nodes during homeostatic conditions is under control of a balance of signals, CCR7 interactions with CCL19 and CCL21 on FRC's that direct migration and retention of naïve CD8⁺ T cells throughout the lymph node compartment and S1PR1 signals that attract the cells toward the efferent lymph.

Inflammatory cytokines can also influence the retention time of naïve CD8⁺ T cells within lymph nodes. In particular, type I interferons (IFN α and IFN β) are produced at high levels during viral infections and will drive the expression of CD69 on naïve CD8⁺ T cells [55]. CD69 will subsequently bind to S1PR1, causing its internalization and degradation, resulting in lymph node retention of the CD8⁺ T cell. CD69 contains a C-type lectin-binding domain,

but seems not to facilitate the interaction with S1PR1. Rather this protein – protein interaction requires the transmembrane region of CD69 and binding results in a conformational change in S1PR1 [56]. Stimulation of the TCR will also result in rapid transcriptional expression of CD69, which allows CD8⁺ T cells to be retained in lymph nodes as they become fully activated by cognate peptide-MHC-I on dendritic cells. In fact, this suppression of S1PR1 expression dominates the retention of CD8⁺ T cells within the lymph node during clonal expansion and does not require CCL19 and CCL21 [41]. Therefore, modulation of S1PR1 expression on naïve CD8⁺ T cells is a critical mechanism that both increases the chance for naïve CD8⁺ T cells to find their cognate antigen during an infection and for the retention of antigen-specific cells in the lymph node for full activation by dendritic cells presenting cognate antigen.

TRAFFICKING OF RECENTLY ACTIVATED, EFFECTOR CD8⁺ T CELLS

When a previously naïve CD8⁺ T cells is subjected to a combination of TCR ligation, co-stimulation, and inflammatory cytokines, these recently activated ‘effector’ CD8⁺ T cells lose expression of CD62L through a combination of protease-mediated cleavage and transcriptional repression [57], and thus, these cells lose the capacity to enter lymph nodes through HEVs. Instead, recently activated CD8⁺ T cells express a cohort of new gene products that control the trafficking and localization patterns of this cell population. As a newly activated CD8⁺ T cell begins to fully divide, its daughter cells will re-express S1PR1 and exit the lymph node. These effector cells will then reenter the circulation and home toward inflamed tissues in order to combat the infection that led to their priming and generation. The cues for leukocytes to be recruited to a site of infection require changes in expression of adhesion molecules and chemokines on the vascular endothelium. Characteristics of inflamed endothelium include expression of a number of adhesion molecules including P- and E-selectin, ICAMs, Vascular Cell Adhesion Molecules (VCAMs), as well as a variety of inflammatory chemokines [58-60]. Thus, matched receptor – ligand interactions between effector CD8⁺ T cells and vascular endothelium regulate the specific recruitment to inflamed or infected tissues.

Generation of P- and E- Selectin Ligands

In contrast to cells of the innate immune system such as neutrophils, which constitutively express P- and E-selectin ligands, the capacity for CD8⁺ T cells to efficiently adhere to P- and E-selectin occurs dynamically and transiently following antigen driven activation. P- and E-selectin expression is readily found on inflamed endothelium and facilitates the initial interaction with activated CD8⁺ T cells that are being attracted to the site of infection or injury. Naïve CD8⁺ T cells cannot bind to either P- or E-selectin and as a result are essentially excluded from entering inflamed tissues. However, following sufficient TCR-mediated activation, a previously naïve CD8⁺ T cell begins expressing the enzymes required to generate O-linked glycosylation structures that bear sialyl-Lewis X motifs on cell surface proteins including P-selectin glycoprotein ligand 1 (PSGL-1) E-selectin Ligand-1, CD44, and CD43, which binds to the c-type lectin domains found on both P- and E-selectin [61,62]. Generation of sialyl-Lewis X motifs on selectin ligands requires a number of glycotransferase enzymes. In particular, activated CD8⁺ T cells express core 2 β 1,6 N-

acetylglucosaminyltransferase 1 (*Gcnt1*), α 1,3 fucosyltransferase 7 (*Fut7*), and probably additional enzymes required to fully generate the core 2 O-glycans that will bind to P- and E-selectin [63,64]. Thus, post-translational glycosylation of selectin ligands is a critical requisite for attraction of effector CD8⁺ T cells to inflamed vascular endothelium.

Expression of Chemokine Receptors and Integrins

The expression of new integrins and chemokine receptors are essential both for localizing effector CD8⁺ T cells to inflamed endothelium as well as migration once the cells have extravasated into the tissue. Chemokine receptors expressed by effector CD8⁺ T cells include CCR4, CCR9, CCR6, and CCR10. Ligands for these chemokine receptors belong to the “inflammatory” family of chemokines, as their expression is most often found at a site of infection. Effector CD8⁺ T cells also strongly increase expression of CXCR3 and ligands for this chemokine receptor include CXCL9, CXCL10, and CXCL11, which collectively are known as the IFN γ -inducible chemokines [65]. In fact, it has recently been demonstrated that antigen-specific CD4⁺ T cell production of IFN γ can influence recruitment of effector CD8⁺ T cells by increasing expression of CXCL9 and CXCL10 at the site of infection [66]. Effector CD8⁺ T cells will also express a variety of integrins including α ₄ β ₁ (Very Late Antigen-4; VLA-4), α ₁ β ₁ (VLA-1) and α ₄ β ₇. In particular, α ₄ β ₇ appears to play a critical role in migration of effector CD8⁺ T cells to the gut due to the expression pattern of its ligand Mucousal Addressin Cell Adhesion Molecule (MadCAM) [67]. Expression of VLA-1 has been shown to impact trafficking and/or retention of CD8⁺ T cells in the lung following influenza virus infection [68]. Therefore, the collective action of newly expressed chemokine receptors and integrins function to recruit effector CD8⁺ T cells to inflamed tissues.

Several studies have suggested that the local microenvironment or specialized dendritic cell subsets influence the expression pattern of selectin ligands, chemokine receptors, and integrins, thus allowing for homing of these newly activated T cells to a specific target tissue, a process known as “imprinting”. For example, the route of infection or vaccination seems to play a significant role in the expression of tissue-specific trafficking molecules that will subsequently be expressed on CD8⁺ T cells following activation [69-72]. Specifically, CD8⁺ T cells primed with dendritic cells from mesenteric lymph nodes or peyer's patches have been shown to express high levels of both α ₄ β ₇ integrin and CCR9, thus establishing a “gut-homing” combination of homing molecules [73]. In contrast, CD8⁺ T cells activated following viral infections of the skin express E-selectin ligands and CCR4, which has been described as a “skin-homing” phenotype [71,74]. Additionally, it has been suggested that acquisition of “skin-homing” molecules appears to be the default pathway following CD8⁺ T cell activation and the “gut-homing” phenotype is generated by additional signals provided by activated dendritic cells.

Because effector CD8⁺ T cells need to re-enter the circulation prior to trafficking to the site of infection, imprinting of specific homing receptors on these cells is an efficient mechanism to ensure that antigen-specific CD8⁺ T cells home to the correct tissue. It should be noted, however, that a number of the studies that identify the process of imprinting were performed using either *in vitro* activation or on CD4⁺ T cell populations and, thus, may not be a

generalizable feature of all CD8⁺ T cells activated *in vivo*. In fact, following a systemic lymphocytic choriomeningitis virus (LCMV) infection, the vast majority of recently activated effector CD8⁺ T cells express P- and E-selectin ligands, $\alpha_4\beta_7$ integrin, and CCR9 [75,76]. This would suggest that the effector CD8⁺ T cells generated following systemic viral infection do not become imprinted and have the potential to localize to both the skin and gut (and possibly many other tissues). Therefore, a contrasting model of effector CD8⁺ T cell trafficking would be that the expression of trafficking receptors on activated CD8⁺ T cells is quite liberal (not tissue-specific) and that the changes in expression of adhesion molecules and chemokines on vascular endothelium following infection or injury is what dictates recruitment to specific tissues. Additional studies will need to be performed to fully determine the molecular and biochemical signals that ultimately regulate effector CD8⁺ T cell trafficking *in vivo* and whether systemic or localized infections drive differential expression of trafficking molecules on CD8⁺ T cells during activation.

Migration within Tissues and Exit via Lymphatics

Although a wealth of information is known regarding the mechanisms controlling recruitment of T cells toward sites of inflammation, far less is known about how these cells migrate within and eventually leave the tissue. Migration within tissues requires CD8⁺ T cells to interact with both a cellular and extracellular matrix network. Several integrins expressed on effector CD8⁺ T cells function as receptors for extracellular matrix components including VLA-4 and $\alpha_v\beta_1$ which bind to fibronectin, and VLA-1 which binds to collagen. Presumably, chemokine stimulated activation of these integrins directs migration. In fact, blocking $\alpha_v\beta_1$ inhibits the migration of activated CD4⁺ T cells within inflamed skin [77], but whether this integrin also controls migration of CD8⁺ T cells in tissues is currently unknown. In addition to its role in regulating recruitment from the circulation, CXCR3 and its ligands have been implicated in directing the migration of activated CD8⁺ T cell in the brain during a chronic *Toxoplasma gondii* infection [78]. Exiting from tissues requires that CD8⁺ T cells enter lymphatic vessels that will passively carry them to the draining lymph node and eventually back to the circulation. Like dendritic cells, CD8⁺ T cells utilize CCR7 to efficiently enter lymphatic vessels before transiting to the draining lymph nodes [79-81]. It has also been reported that S1PR1 also guides CD8⁺ T cells toward afferent lymphatic vessels [82]. If this is indeed the case, this would suggest that CCR7 and S1PR1 signaling act synergistically in tissues to recruit CD8⁺ T cells to the draining lymphatics and that inflammatory chemokines might act to retain them. However, whether this model accurately predicts the migratory behavior of activated CD8⁺ T cells in tissues has not been fully characterized.

TRAFFICKING AND LOCALIZATION OF ANTIGEN-EXPERIENCED MEMORY CD8⁺ T CELL POPULATIONS

Following resolution of the contraction phase of the CD8⁺ T cell response to antigen, the surviving cells differentiate into long-lived 'memory' populations. Although these populations of cells closely resemble naïve CD8⁺ T cells when comparing overall gene expression profiles [83], many important functional differences clearly distinguishes a naïve CD8⁺ T cell from an antigen-experienced, memory CD8⁺ T cell. Specifically, these cells are

now able to produce cytokines such as IFN γ [84], rapidly kill cells with perforin and granzyme following antigenic stimulation [85], and undergo substantial homeostatic proliferation [86], which may contribute to the longevity of the population. Furthermore, in contrast to naïve CD8 $^{+}$ T cells which are restricted to entering lymph nodes and effector CD8 $^{+}$ T cells which are attracted primarily to inflamed tissues, memory CD8 $^{+}$ T cells exhibit a diverse trafficking pattern that encompasses features of both naïve and effector CD8 $^{+}$ T cells. This results in populations of memory CD8 $^{+}$ T cells to be distributed throughout the body, both in tissues as well as secondary lymphoid organs [87,88].

The ‘Central’ and ‘Effector’ Memory T cell Paradigm

Shortly after the discovery that T cells utilized the selectin CD62L and the chemokine receptor CCR7 to directly enter lymph nodes by crossing HEVs, it was identified that in humans, some antigen-experienced memory CD8 $^{+}$ T cells (and CD4 $^{+}$ T cells) expressed the combination of these receptors while others did not [89,90]. This resulted in categorizing memory T cell populations into one of two broad categories based on this trafficking ability. Memory CD8 $^{+}$ T cells that expressed CD62L and CCR7 were labeled “Central Memory” (T_{CM}), due to their capacity to directly enter lymph nodes and undergo robust expansion following re-stimulation. In contrast, memory CD8 $^{+}$ T cells that lacked expression of these receptors were termed “Effector Memory” (T_{EM}), as they are largely absent from lymph nodes, localize more preferentially to peripheral tissues and exhibit enhanced killing capacity. This paradigm has been also verified using mouse models of infection, as CD62L $^{-/-}$ memory CD8 $^{+}$ T cells are almost entirely excluded from lymph nodes, but readily localize to the spleen and other tissues [91]. Therefore, the expression CD62L and CCR7 is critical for localizing memory CD8 $^{+}$ T cells into secondary lymphoid organs where they can undergo secondary expansion following stimulation by antigen on mature dendritic cells.

Conceivably, the generation of both T_{CM} and T_{EM} CD8 $^{+}$ T cells occurs to optimize host protection against re-infection, where T_{EM} can provide a first line of defense in tissues and T_{CM} can undergo re-expansion in draining lymph nodes. In fact, numerous studies have examined the protective capacity these two memory subsets provide and the results suggest that protection is largely pathogen specific. For example, T_{EM} CD8 $^{+}$ T cells are potent mediators of host protection following infection with *Listeria monocytogenes*, a gram-positive bacteria that infects the spleen and liver and also against both a systemic and local Vaccinia virus infection [91-93]. In contrast, T_{CM} CD8 $^{+}$ T cells are superior in preventing a chronic LCMV infection due to both their lymph node localization and their potent recall potential [91,94]. T_{CM} CD8 $^{+}$ T cells have also been shown to be more potent contributors to anti-tumor immunity than T_{EM} due to their lymph node homing capacity [95]. Thus, these studies suggest that the differential localization of memory CD8 $^{+}$ T cell subsets plays a critical role in providing protective immunity against a variety of pathogens and disease conditions.

The ratio of T_{CM} to T_{EM} populations that exist following a primary infection or vaccination is heavily influenced by the presence (or absence) of inflammatory cytokines. High levels of inflammatory cytokines such as type I interferons or IL-12 during CD8 $^{+}$ T cell priming and expansion will drive not only more extensive proliferation, but also the formation of more

T_{EM} in the subsequent memory population [96]. Conversely, CD8⁺ T cells primed in a low inflammatory environment expand less, but predominantly form T_{CM}. In addition, priming of naïve CD8⁺ T cells in a low inflammatory environment allows for rapid boosting following secondary vaccination or infection [97]. Therefore, exposure to inflammatory cytokines following infection or vaccination not only impacts the immediate proliferative response to antigen, but also subsequently affects the overall distribution, localization, and boosting capacity of memory CD8⁺ T cells following contraction.

Recruitment of Memory CD8⁺ T cells to Inflamed Tissues

Following an injury or infection, memory CD8⁺ T cells rapidly localize to the inflamed tissue in an antigen-independent manner. This biological process was first observed when memory CD8⁺ T cells specific for one respiratory virus were recruited to the site of infection following subsequent challenge with a different respiratory virus [98]. Thus, antigen-experienced memory CD8⁺ T cells acquire the capacity to rapidly localize to an inflamed environment, regardless of whether they will be able to subsequently recognize the antigens expressed by the pathogen. Therefore, following re-infection, antigen-specific memory CD8⁺ T will be recruited to the site of infection in two phases. Initially, memory CD8⁺ T cells will traffic to the inflamed environment regardless of antigen specificity and provide immediate protection if cognate antigen is present. The second phase occurs as previously T_{CM} CD8⁺ T cells in the draining lymph node undergo antigen-driven expansion and subsequently localize to the site of infection [99]. The overall set of mechanisms that control the antigen-independent recruitment of memory CD8⁺ T cells to sites of infection are mostly still unknown, although the chemokine receptors CCR5 and CXCR3 have been shown to impact recruitment of memory CD8⁺ T cells to the lung airways in this manner [100,101].

The ability to modulate binding to P- and E-selectin has also been shown to contribute to localization of memory CD8⁺ T cells *in vivo* [76]. Most memory CD8⁺ T cells do not bind to P- or E-selectin during homeostatic conditions. However, it has been recently demonstrated that memory CD8⁺ T cells modulate their ability to generate P- and E-selectin ligands during an infection or inflammatory episode, and this also occurs in an antigen-independent manner. Specifically, memory CD8⁺ T cells exhibit an open chromatin conformation at the *Gcnt1* gene locus, the enzyme responsible for core 2 O-glycan synthesis in T cells. In response to inflammatory IL-15, memory CD8⁺ T cells will express *Gcnt1*, resulting in the generation of core 2 O-glycans that serve as P- and E-selectin ligands (Figure 3). These antigen-experienced CD8⁺ T cells are then drawn specifically toward inflamed tissues and, if cognate antigen is present, provide host protection against infection [76]. Importantly, naïve CD8⁺ T cells do not express core 2 O-glycans in response to IL-15 stimulation due to epigenetic differences at the *Gcnt1* gene locus, and thus, are not able to localize to inflamed tissues using this mechanism. Overall, these studies collectively suggest that the protection mediated by circulating memory CD8⁺ T cells requires an antigen-independent recruitment phase, followed by antigen-dependent elimination of infected cells.

Trafficking of Memory CD8⁺ T cells Following Multiple Antigen Stimulations

Recent experimental studies have demonstrated that CD8⁺ T cells that are exposed to multiple antigenic challenges (like what would occur during recurring exposure to infections

or booster immunizations) exhibit a transcriptional gene profile and phenotype that resembles a “terminally differentiated T_{EM}” population of memory cells [102,92,103]. Similar types of memory CD8⁺ T cell populations are readily found following chronic or latent viral infections, such as those specific for certain epitopes of murine cytomegalovirus (MCMV) [104]. As suggested by the T_{EM} phenotype, these cells strongly reduce their expression of CD62L and CCR7, greatly diminishing their lymph node homing potential and undergo limited proliferation following antigen re-challenge. However, these cell populations express higher levels of chemokine receptors and integrins that would regulate recruitment to inflamed tissues, such as CCR5 and VLA-1. Accordingly, these repeatedly stimulated CD8⁺ T cells are now enriched in peripheral tissues such as the lung. Collectively, these studies suggest that populations of CD8⁺ T cells that are continually stimulated by antigen are excluded from secondary lymphoid organs and are enriched in peripheral tissues, where they can serve as a first line of defense against re-infection.

Tissue-Resident Memory CD8⁺ T cells

In the past few years, the major advance in our overall understanding of CD8⁺ T cell trafficking has actually focused much more on the “lack thereof”. As discussed previously, memory CD8⁺ T cells are often defined based on their expression of lymph node homing receptors and the cells that lack those receptors are typically labeled T_{EM}. However, recent experimental studies provide compelling evidence that there is a specialized subset of CD8⁺ T_{EM} that do not re-enter the circulation following the resolution of an infection and are retained in tissues such as the skin, lung, and gut, and have been named “resident memory” CD8⁺ T cells (T_{RM}) [105-108]. Besides exhibiting a unique gene expression profile [109], these cells provide potent protection against a number of pathogens following re-infection [110-112]. Because of the superior protective capacity of these cell populations compared to circulating memory CD8⁺ T cells, there has been considerable interest in studying the molecular and biological mechanisms that regulate the formation of T_{RM}, especially with regards to vaccine design.

Like typical T_{EM}, T_{RM} do not express CD62L, but rather have been identified by the expression of the α_E integrin (CD103) chain of $\alpha_E\beta_7$ and CD69. The ligand for $\alpha_E\beta_7$ is E-cadherin [113] and it is believed that expression of this integrin – ligand interaction helps retain T_{RM} specifically in tissues, as CD103^{-/-} CD8⁺ T cells fail to generate T_{RM} following herpes simplex virus (HSV) infection [109]. As mentioned previously, CD69 targets S1PR1 for degradation and S1PR1 has been implicated in guiding CD8⁺ T cells out of tissues. In fact, transcriptional downregulation of S1PR1 also contributes to the generation of T_{RM} in the skin [114]. This finding also supports the mechanism that CD8⁺ T cells utilize S1PR1 for exiting tissues. Therefore, these studies demonstrate that expression of CD103 and CD69 not only can be used as “markers” for the identification of T_{RM} CD8⁺ T cells populations, but also contribute to their overall retention and differentiation.

The mechanisms controlling both the establishment and maintenance of T_{RM} CD8⁺ T cells have begun to be elucidated. Interestingly, the presence of cognate antigen does not appear to be necessary for the generation of T_{RM} as transfer of *in vitro* activated CD8⁺ T cells also become T_{RM} after localizing to inflamed tissues [115]. Rather, several cytokines have been

implicated in driving T_{RM} generation. In particular, Transforming Growth Factor (TGF)- β seems to be potent driver of T_{RM} differentiation, although IL-33 and Tumor Necrosis Factor alpha (TNF γ) may also contribute [106,109,116,114]. Like conventional, circulating memory CD8⁺ T cells, IL-15 stimulates the survival of these cells in the tissues, even though they express low levels of IL-2R β (the receptor for IL-15) and do not undergo significant homeostatic proliferation [105,109]. Collectively, these studies suggest a model where naïve CD8⁺ T cells are initially activated in the draining lymph node and subsequently re-enter the circulation. These recently activated effector CD8⁺ T cells will now home to tissue and upon exposure to TGF- β (and possibly TNF α and IL-33), will subsequently differentiate into a T_{RM} (Figure 4).

CONCLUDING REMARKS

As described in this review, the trafficking and localization of different CD8⁺ T cells will vary considerably based on a number of factors that ultimately influences the expression of selectin and selectin ligands, chemokine receptors, and integrins. The specific molecular and biochemical signals that influence the expression of various homing receptors during CD8⁺ cell activation and memory differentiation still remain mostly undefined and it is also unclear whether “imprinting” is a generalizable mechanism or if it only occurs during certain biological settings. In addition, our overall understanding of how antigen-experienced memory CD8⁺ T cells traffic is still rather limited, which is significant because as we age, most CD8⁺ T cells in humans exhibit an antigen-experienced, memory phenotype. The recent identification and characterization of the T_{RM} subset of memory CD8⁺ T cells has generated considerable interest in the field and suggests there are probably additional, specialized memory CD8⁺ T cells beyond the broadly defined T_{CM} and T_{EM} subsets. In fact, recent evidence suggests that memory CD4⁺ T cells do not use CCR7 for homing to lymph nodes and CCR7-deficiency only has minimal effect on memory CD8⁺ T cell lymph node homing [117]. Therefore, even the most fundamental principles of memory CD8⁺ T cell trafficking are still being disputed in the literature. Overall, by fully characterizing certain memory CD8⁺ T cells subsets, we will be able to make more sophisticated predictions of the ability for these cells to traffic to different tissues and how to influence this process therapeutically. These fundamental principles will be critical for vaccine design, optimizing cancer immunotherapy strategies and treating autoimmune disorders.

ACKNOWLEDGEMENTS

I would like to thank Dr. Amanda Lund for helpful discussion and critical review of the manuscript. Research in the Nolz laboratory is supported by the National Institute of Health Grant K22AI102981 and the OHSU Knight Cancer Center Support Grant NIH P30-CA069533.

REFERENCES

1. Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. *Immunity*. 2011; 35(2): 161–168. doi:10.1016/j.immuni.2011.07.010. [PubMed: 21867926]
2. Harty JT, Tvinnereim AR, White DW. CD8+ T cell effector mechanisms in resistance to infection. *Annual review of immunology*. 2000; 18:275–308. doi:10.1146/annurev.immunol.18.1.275.

3. Harty JT, Badovinac VP. Shaping and reshaping CD8+ T-cell memory. *Nature reviews Immunology*. 2008; 8(2):107–119. doi:10.1038/nri2251.
4. Butler NS, Nolz JC, Harty JT. Immunologic considerations for generating memory CD8 T cells through vaccination. *Cellular microbiology*. 2011; 13(7):925–933. doi:10.1111/j.1462-5822.2011.01594.x. [PubMed: 21501363]
5. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. *Nature reviews Immunology*. 2002; 2(4):251–262. doi:10.1038/nri778.
6. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. *Immunological reviews*. 2006; 211:214–224. doi:10.1111/j.0105-2896.2006.00391.x. [PubMed: 16824130]
7. Melero I, Rouzaut A, Motz GT, Coukos G. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. *Cancer discovery*. 2014; 4(5):522–526. doi:10.1158/2159-8290.CD-13-0985. [PubMed: 24795012]
8. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. *Science*. 2006; 313(5795):1960–1964. doi:10.1126/science.1129139. [PubMed: 17008531]
9. Newell EW, Sigal N, Bendall SC, Nolan GP, Davis MM. Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. *Immunity*. 2012; 36(1):142–152. doi:10.1016/j.immuni.2012.01.002. [PubMed: 22265676]
10. Chen G, Shankar P, Lange C, Valdez H, Skolnik PR, Wu L, Manjunath N, Lieberman J. CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection. *Blood*. 2001; 98(1):156–164. [PubMed: 11418475]
11. Su LF, Kidd BA, Han A, Kotzin JJ, Davis MM. Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. *Immunity*. 2013; 38(2):373–383. doi:10.1016/j.immuni.2012.10.021. [PubMed: 23395677]
12. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, Germon S, Del Rio C, Mulligan MJ, Staprans SI, Altman JD, Feinberg MB, Ahmed R. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. *Immunity*. 2008; 28(5):710–722. doi:10.1016/j.immuni.2008.02.020. [PubMed: 18468462]
13. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, Easterbrook P, Salio M, Cerundolo V, McMichael AJ, Rowland-Jones SL. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. *Nature medicine*. 2002; 8(4):379–385. doi:10.1038/nm0402-379.
14. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. *Nature reviews Immunology*. 2007; 7(9):678–689. doi:10.1038/nri2156.
15. Gebhardt T, Whitney PG, Zaid A, Mackay LK, Brooks AG, Heath WR, Carbone FR, Mueller SN. Different patterns of peripheral migration by memory CD4+ and CD8+ T cells. *Nature*. 2011; 477(7363):216–219. doi:10.1038/nature10339. [PubMed: 21841802]
16. Klonowski KD, Williams KJ, Marzo AL, Blair DA, Lingenheld EG, Lefrancois L. Dynamics of blood-borne CD8 memory T cell migration in vivo. *Immunity*. 2004; 20(5):551–562. [PubMed: 15142524]
17. Obar JJ, Khanna KM, Lefrancois L. Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. *Immunity*. 2008; 28(6):859–869. doi:10.1016/j.immuni.2008.04.010. [PubMed: 18499487]
18. Blattman JN, Antia R, Sourdive DJ, Wang X, Kaech SM, Murali-Krishna K, Altman JD, Ahmed R. Estimating the precursor frequency of naive antigen-specific CD8 T cells. *The Journal of experimental medicine*. 2002; 195(5):657–664. [PubMed: 11877489]

19. Girard JP, Moussion C, Forster R. HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. *Nature reviews Immunology*. 2012; 12(11):762–773. doi:10.1038/nri3298.
20. Mackay CR, Marston WL, Dudler L. Naive and memory T cells show distinct pathways of lymphocyte recirculation. *The Journal of experimental medicine*. 1990; 171(3):801–817. [PubMed: 2307933]
21. Bruehl RE, Bertozzi CR, Rosen SD. Minimal sulfated carbohydrates for recognition by L-selectin and the MECA-79 antibody. *The Journal of biological chemistry*. 2000; 275(42):32642–32648. doi:10.1074/jbc.M001703200. [PubMed: 10938267]
22. Rosen SD. Ligands for L-selectin: homing, inflammation, and beyond. *Annual review of immunology*. 2004; 22:129–156. doi:10.1146/annurev.immunol.21.090501.080131.
23. Umemoto E, Tanaka T, Kanda H, Jin S, Tohya K, Otani K, Matsutani T, Matsumoto M, Ebisuno Y, Jang MH, Fukuda M, Hirata T, Miyasaka M. Nepmucin, a novel HEV sialomucin, mediates L-selectin-dependent lymphocyte rolling and promotes lymphocyte adhesion under flow. *The Journal of experimental medicine*. 2006; 203(6):1603–1614. doi:10.1084/jem.20052543. [PubMed: 16754720]
24. Mitoma J, Bao X, Petryanik B, Schaerli P, Gauguet JM, Yu SY, Kawashima H, Saito H, Ohtsubo K, Marth JD, Khoo KH, von Andrian UH, Lowe JB, Fukuda M. Critical functions of N-glycans in L-selectin-mediated lymphocyte homing and recruitment. *Nature immunology*. 2007; 8(4):409–418. doi:10.1038/ni1442. [PubMed: 17334369]
25. Diacovo TG, Catalina MD, Siegelman MH, von Andrian UH. Circulating activated platelets reconstitute lymphocyte homing and immunity in L-selectin-deficient mice. *The Journal of experimental medicine*. 1998; 187(2):197–204. [PubMed: 9432977]
26. Diacovo TG, Puri KD, Warnock RA, Springer TA, von Andrian UH. Platelet-mediated lymphocyte delivery to high endothelial venules. *Science*. 1996; 273(5272):252–255. [PubMed: 8662511]
27. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. *Annual review of immunology*. 2007; 25:787–820. doi:10.1146/annurev.immunol.24.021605.090529.
28. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. *Immunity*. 2000; 12(2):121–127. [PubMed: 10714678]
29. Neves SR, Ram PT, Iyengar R. G protein pathways. *Science*. 2002; 296(5573):1636–1639. doi:10.1126/science.1071550. [PubMed: 12040175]
30. Forster R, Davalos-Misslitz AC, Rot A. CCR7 and its ligands: balancing immunity and tolerance. *Nature reviews Immunology*. 2008; 8(5):362–371. doi:10.1038/nri2297.
31. Baekkevold ES, Yamanaka T, Palframan RT, Carlsen HS, Reinholt FP, von Andrian UH, Brandtzaeg P, Haraldsen G. The CCR7 ligand elc (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. *The Journal of experimental medicine*. 2001; 193(9):1105–1112. [PubMed: 11342595]
32. Bao X, Moseman EA, Saito H, Petryniak B, Thiriot A, Hatakeyama S, Ito Y, Kawashima H, Yamaguchi Y, Lowe JB, von Andrian UH, Fukuda M. Endothelial heparan sulfate controls chemokine presentation in recruitment of lymphocytes and dendritic cells to lymph nodes. *Immunity*. 2010; 33(5):817–829. doi:10.1016/j.immuni.2010.10.018. [PubMed: 21093315]
33. Kinashi T. Intracellular signalling controlling integrin activation in lymphocytes. *Nature reviews Immunology*. 2005; 5(7):546–559. doi:10.1038/nri1646.
34. Warnock RA, Askari S, Butcher EC, von Andrian UH. Molecular mechanisms of lymphocyte homing to peripheral lymph nodes. *The Journal of experimental medicine*. 1998; 187(2):205–216. [PubMed: 9432978]
35. Park EJ, Peixoto A, Imai Y, Goodarzi A, Cheng G, Carman CV, von Andrian UH, Shimaoka M. Distinct roles for LFA-1 affinity regulation during T-cell adhesion, diapedesis, and interstitial migration in lymph nodes. *Blood*. 2010; 115(8):1572–1581. doi:10.1182/blood-2009-08-237917. [PubMed: 20023213]
36. Moussion C, Girard JP. Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. *Nature*. 2011; 479(7374):542–546. doi:10.1038/nature10540. [PubMed: 22080953]

37. Munoz MA, Biro M, Weninger W. T cell migration in intact lymph nodes in vivo. *Current opinion in cell biology*. 2014; 30:17–24. doi:10.1016/j.ceb.2014.05.002. [PubMed: 24907445]
38. Okada T, Cyster JG. CC chemokine receptor 7 contributes to Gi-dependent T cell motility in the lymph node. *Journal of immunology*. 2007; 178(5):2973–2978.
39. Worbs T, Mempel TR, Bolter J, von Andrian UH, Forster R. CCR7 ligands stimulate the intranodal motility of T lymphocytes in vivo. *The Journal of experimental medicine*. 2007; 204(3):489–495. doi:10.1084/jem.20061706. [PubMed: 17325198]
40. Bajenoff M, Egen JG, Koo LY, Laugier JP, Brau F, Glaichenhaus N, Germain RN. Stromal cell networks regulate lymphocyte entry, migration, and territoriality in lymph nodes. *Immunity*. 2006; 25(6):989–1001. doi:10.1016/j.immuni.2006.10.011. [PubMed: 17112751]
41. Denton AE, Roberts EW, Linterman MA, Fearon DT. Fibroblastic reticular cells of the lymph node are required for retention of resting but not activated CD8+ T cells. *Proceedings of the National Academy of Sciences of the United States of America*. 2014; 111(33):12139–12144. doi:10.1073/pnas.1412910111. [PubMed: 25092322]
42. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. *Nature*. 2006; 440(7086):890–895. doi:10.1038/nature04651. [PubMed: 16612374]
43. Mempel TR, Henrickson SE, Von Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. *Nature*. 2004; 427(6970):154–159. doi:10.1038/nature02238. [PubMed: 14712275]
44. Henrickson SE, Mempel TR, Mazo IB, Liu B, Artyomov MN, Zheng H, Peixoto A, Flynn MP, Senman B, Junt T, Wong HC, Chakraborty AK, von Andrian UH. T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. *Nature immunology*. 2008; 9(3):282–291. doi:10.1038/ni1559. [PubMed: 18204450]
45. Henrickson SE, Perro M, Loughhead SM, Senman B, Stutte S, Quigley M, Alexe G, Iannaccone M, Flynn MP, Omid S, Jesneck JL, Imam S, Mempel TR, Mazo IB, Haining WN, von Andrian UH. Antigen availability determines CD8(+) T cell-dendritic cell interaction kinetics and memory fate decisions. *Immunity*. 2013; 39(3):496–507. doi:10.1016/j.immuni.2013.08.034. [PubMed: 24054328]
46. Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. *Nature*. 1989; 341(6243):619–624. doi:10.1038/341619a0. [PubMed: 2477710]
47. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML. The immunological synapse: a molecular machine controlling T cell activation. *Science*. 1999; 285(5425):221–227. [PubMed: 10398592]
48. Hickman HD, Takeda K, Skon CN, Murray FR, Hensley SE, Loomis J, Barber GN, Bennink JR, Yewdell JW. Direct priming of antiviral CD8+ T cells in the peripheral interfollicular region of lymph nodes. *Nature immunology*. 2008; 9(2):155–165. doi:10.1038/ni1557. [PubMed: 18193049]
49. John B, Harris TH, Tait ED, Wilson EH, Gregg B, Ng LG, Mrass P, Roos DS, Dzierszinski F, Weninger W, Hunter CA. Dynamic Imaging of CD8(+) T cells and dendritic cells during infection with *Toxoplasma gondii*. *PLoS pathogens*. 2009; 5(7):e1000505. doi:10.1371/journal.ppat.1000505. [PubMed: 19578440]
50. Mandl JN, Liou R, Klauschen F, Vriskoop N, Monteiro JP, Yates AJ, Huang AY, Germain RN. Quantification of lymph node transit times reveals differences in antigen surveillance strategies of naive CD4+ and CD8+ T cells. *Proceedings of the National Academy of Sciences of the United States of America*. 2012; 109(44):18036–18041. doi:10.1073/pnas.1211717109. [PubMed: 23071319]
51. Tomura M, Yoshida N, Tanaka J, Karasawa S, Miwa Y, Miyawaki A, Kanagawa O. Monitoring cellular movement in vivo with photoconvertible fluorescence protein “Kaede” transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America*. 2008; 105(31):10871–10876. doi:10.1073/pnas.0802278105. [PubMed: 18663225]
52. Cyster JG, Schwab SR. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. *Annual review of immunology*. 2012; 30:69–94. doi:10.1146/annurevimmunol-020711-075011.

53. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. *Science*. 2005; 309(5741):1735–1739. doi:10.1126/science.1113640. [PubMed: 16151014]
54. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D, Keohane C, Rosenbach M, Hale J, Lynch CL, Rupprecht K, Parsons W, Rosen H. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. *Science*. 2002; 296(5566): 346–349. doi:10.1126/science.1070238. [PubMed: 11923495]
55. Shioh LR, Rosen DB, Brdickova N, Xu Y, An J, Lanier LL, Cyster JG, Matloubian M. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. *Nature*. 2006; 440(7083):540–544. doi:10.1038/nature04606. [PubMed: 16525420]
56. Bankovich AJ, Shioh LR, Cyster JG. CD69 suppresses sphingosine 1-phosphate receptor-1 (S1P1) function through interaction with membrane helix 4. *The Journal of biological chemistry*. 2010; 285(29):22328–22337. doi:10.1074/jbc.M110.123299. [PubMed: 20463015]
57. Chen A, Engel P, Tedder TF. Structural requirements regulate endoproteolytic release of the L-selectin (CD62L) adhesion receptor from the cell surface of leukocytes. *The Journal of experimental medicine*. 1995; 182(2):519–530. [PubMed: 7543141]
58. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. *Nature reviews Immunology*. 2007; 7(10):803–815. doi:10.1038/nri2171.
59. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. *Annual review of immunology*. 1993; 11:767–804. doi:10.1146/annurev.iy.11.040193.004003.
60. Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA. Leukocyte extravasation: chemokine transport and presentation by the endothelium. *Blood*. 2002; 100(12):3853–3860. doi: 10.1182/blood.V100.12.3853. [PubMed: 12433694]
61. Carlow DA, Gossens K, Naus S, Veerman KM, Seo W, Ziltener HJ. PSGL-1 function in immunity and steady state homeostasis. *Immunological reviews*. 2009; 230(1):75–96. doi:10.1111/j. 1600-065X.2009.00797.x. [PubMed: 19594630]
62. Hidalgo A, Peired AJ, Wild MK, Vestweber D, Frenette PS. Complete identification of E-selectin ligands on neutrophils reveals distinct functions of PSGL-1, ESL-1, and CD44. *Immunity*. 2007; 26(4):477–489. doi:10.1016/j.immuni.2007.03.011. [PubMed: 17442598]
63. Ley K, Kansas GS. Selectins in T-cell recruitment to non-lymphoid tissues and sites of inflammation. *Nature reviews Immunology*. 2004; 4(5):325–335. doi:10.1038/nri1351.
64. Marth JD, Grewal PK. Mammalian glycosylation in immunity. *Nature reviews Immunology*. 2008; 8(11):874–887. doi:10.1038/nri2417.
65. Groom JR, Luster AD. CXCR3 in T cell function. *Experimental cell research*. 2011; 317(5):620–631. doi:10.1016/j.yexcr.2010.12.017. [PubMed: 21376175]
66. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. *Nature*. 2009; 462(7272):510–513. doi:10.1038/nature08511. [PubMed: 19898495]
67. Lefrancois L, Parker CM, Olson S, Muller W, Wagner N, Schon MP, Puddington L. The role of beta7 integrins in CD8 T cell trafficking during an antiviral immune response. *The Journal of experimental medicine*. 1999; 189(10):1631–1638. [PubMed: 10330442]
68. Ray SJ, Franki SN, Pierce RH, Dimitrova S, Kotliansky V, Sprague AG, Doherty PC, de Fougerolles AR, Topham DJ. The collagen binding alpha1beta1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection. *Immunity*. 2004; 20(2): 167–179. [PubMed: 14975239]
69. Ferguson AR, Engelhard VH. CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and coexpress multiple chemokine receptors. *Journal of immunology*. 2010; 184(8):4079–4086. doi:10.4049/jimmunol.0901903.
70. Dudda JC, Simon JC, Martin S. Dendritic cell immunization route determines CD8+ T cell trafficking to inflamed skin: role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets. *Journal of immunology*. 2004; 172(2):857–863.
71. Liu L, Fuhlbrigge RC, Karibian K, Tian T, Kupper TS. Dynamic programming of CD8+ T cell trafficking after live viral immunization. *Immunity*. 2006; 25(3):511–520. doi:10.1016/j.immuni. 2006.06.019. [PubMed: 16973385]

72. Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, Roseblatt M, Von Andrian UH. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. *Nature*. 2003; 424(6944):88–93. doi:10.1038/nature01726. [PubMed: 12840763]
73. Mora JR, Cheng G, Picarella D, Briskin M, Buchanan N, von Andrian UH. Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. *The Journal of experimental medicine*. 2005; 201(2):303–316. doi:10.1084/jem.20041645. [PubMed: 15642741]
74. Campbell DJ, Butcher EC. Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. *The Journal of experimental medicine*. 2002; 195(1):135–141. [PubMed: 11781372]
75. Masopust D, Choo D, Vezys V, Wherry EJ, Duraiswamy J, Akondy R, Wang J, Casey KA, Barber DL, Kawamura KS, Fraser KA, Webby RJ, Brinkmann V, Butcher EC, Newell KA, Ahmed R. Dynamic T cell migration program provides resident memory within intestinal epithelium. *The Journal of experimental medicine*. 2010; 207(3):553–564. doi:10.1084/jem.20090858. [PubMed: 20156972]
76. Nolz JC, Harty JT. IL-15 regulates memory CD8+ T cell O-glycan synthesis and affects trafficking. *The Journal of clinical investigation*. 2014; 124(3):1013–1026. doi:10.1172/JCI72039. [PubMed: 24509081]
77. Overstreet MG, Gaylo A, Angermann BR, Hughson A, Hyun YM, Lambert K, Acharya M, Billroth-Maclurg AC, Rosenberg AF, Topham DJ, Yagita H, Kim M, Lacy-Hulbert A, Meier-Schellersheim M, Fowell DJ. Inflammation-induced interstitial migration of effector CD4(+) T cells is dependent on integrin alphaV. *Nature immunology*. 2013; 14(9):949–958. doi:10.1038/ni.2682. [PubMed: 23933892]
78. Harris TH, Banigan EJ, Christian DA, Konradt C, Tait Wojno ED, Norose K, Wilson EH, John B, Weninger W, Luster AD, Liu AJ, Hunter CA. Generalized Levy walks and the role of chemokines in migration of effector CD8+ T cells. *Nature*. 2012; 486(7404):545–548. doi:10.1038/nature11098. [PubMed: 22722867]
79. Jennrich S, Lee MH, Lynn RC, Dewberry K, Debes GF. Tissue exit: a novel control point in the accumulation of antigen-specific CD8 T cells in the influenza A virus-infected lung. *Journal of virology*. 2012; 86(7):3436–3445. doi:10.1128/JVI.07025-11. [PubMed: 22278253]
80. Bromley SK, Thomas SY, Luster AD. Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. *Nature immunology*. 2005; 6(9):895–901. doi:10.1038/ni1240. [PubMed: 16116469]
81. Debes GF, Arnold CN, Young AJ, Krautwald S, Lipp M, Hay JB, Butcher EC. Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. *Nature immunology*. 2005; 6(9):889–894. doi:10.1038/ni1238. [PubMed: 16116468]
82. Ledgerwood LG, Lal G, Zhang N, Garin A, Esses SJ, Ginhoux F, Merad M, Peche H, Lira SA, Ding Y, Yang Y, He X, Schuchman EH, Allende ML, Ochando JC, Bromberg JS. The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. *Nature immunology*. 2008; 9(1):42–53. doi:10.1038/ni1534. [PubMed: 18037890]
83. Weng NP, Araki Y, Subedi K. The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation. *Nature reviews Immunology*. 2012; 12(4):306–315. doi:10.1038/nri3173.
84. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, Slansky J, Ahmed R. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. *Immunity*. 1998; 8(2):177–187. [PubMed: 9491999]
85. Barber DL, Wherry EJ, Ahmed R. Cutting edge: rapid in vivo killing by memory CD8 T cells. *Journal of immunology*. 2003; 171(1):27–31.
86. Schluns KS, Lefrançois L. Cytokine control of memory T-cell development and survival. *Nature reviews Immunology*. 2003; 3(4):269–279. doi:10.1038/nri1052.
87. Nolz JC, Starbeck-Miller GR, Harty JT. Naive, effector and memory CD8 T-cell trafficking: parallels and distinctions. *Immunotherapy*. 2011; 3(10):1223–1233. doi:10.2217/imt.11.100. [PubMed: 21995573]

88. Masopust D, Vezys V, Usherwood EJ, Cauley LS, Olson S, Marzo AL, Ward RL, Woodland DL, Lefrançois L. Activated primary and memory CD8 T cells migrate to nonlymphoid tissues regardless of site of activation or tissue of origin. *Journal of immunology*. 2004; 172(8):4875–4882.
89. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. *Annual review of immunology*. 2004; 22:745–763. doi: 10.1146/annurev.immunol.22.012703.104702.
90. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature*. 1999; 401(6754):708–712. doi: 10.1038/44385. [PubMed: 10537110]
91. Nolz JC, Harty JT. Protective capacity of memory CD8+ T cells is dictated by antigen exposure history and nature of the infection. *Immunity*. 2011; 34(5):781–793. doi:10.1016/j.immuni.2011.03.020. [PubMed: 21549619]
92. Jabbari A, Harty JT. Secondary memory CD8+ T cells are more protective but slower to acquire a central-memory phenotype. *The Journal of experimental medicine*. 2006; 203(4):919–932. doi: 10.1084/jem.20052237. [PubMed: 16567385]
93. Olson JA, McDonald-Hyman C, Jameson SC, Hamilton SE. Effector-like CD8(+) T cells in the memory population mediate potent protective immunity. *Immunity*. 2013; 38(6):1250–1260. doi: 10.1016/j.immuni.2013.05.009. [PubMed: 23746652]
94. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R, von Andrian UH, Ahmed R. Lineage relationship and protective immunity of memory CD8 T cell subsets. *Nature immunology*. 2003; 4(3):225–234. doi:10.1038/ni889. [PubMed: 12563257]
95. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102(27):9571–9576. doi:10.1073/pnas.0503726102. [PubMed: 15980149]
96. Haring JS, Badovinac VP, Harty JT. Inflaming the CD8+ T cell response. *Immunity*. 2006; 25(1):19–29. doi:10.1016/j.immuni.2006.07.001. [PubMed: 16860754]
97. Badovinac VP, Messingham KA, Jabbari A, Haring JS, Harty JT. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. *Nature medicine*. 2005; 11(7):748–756. doi:10.1038/nm1257.
98. Ely KH, Cauley LS, Roberts AD, Brennan JW, Cookenham T, Woodland DL. Nonspecific recruitment of memory CD8+ T cells to the lung airways during respiratory virus infections. *Journal of immunology*. 2003; 170(3):1423–1429.
99. Woodland DL, Kohlmeier JE. Migration, maintenance and recall of memory T cells in peripheral tissues. *Nature reviews Immunology*. 2009; 9(3):153–161. doi:10.1038/nri2496.
100. Kohlmeier JE, Miller SC, Smith J, Lu B, Gerard C, Cookenham T, Roberts AD, Woodland DL. The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections. *Immunity*. 2008; 29(1):101–113. doi:10.1016/j.immuni.2008.05.011. [PubMed: 18617426]
101. Slutter B, Pewe LL, Kaech SM, Harty JT. Lung airway-surveilling CXCR3(hi) memory CD8(+) T cells are critical for protection against influenza A virus. *Immunity*. 2013; 39(5):939–948. doi: 10.1016/j.immuni.2013.09.013. [PubMed: 24238342]
102. Wirth TC, Xue HH, Rai D, Sabel JT, Bair T, Harty JT, Badovinac VP. Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8(+) T cell differentiation. *Immunity*. 2010; 33(1):128–140. doi:10.1016/j.immuni.2010.06.014. [PubMed: 20619696]
103. Masopust D, Ha SJ, Vezys V, Ahmed R. Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. *Journal of immunology*. 2006; 177(2):831–839.
104. Munks MW, Cho KS, Pinto AK, Sierro S, Klenerman P, Hill AB. Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. *Journal of immunology*. 2006; 177(1):450–458.

105. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. *Nature immunology*. 2009; 10(5):524–530. doi:10.1038/ni.1718. [PubMed: 19305395]
106. Casey KA, Fraser KA, Schenkel JM, Moran A, Abt MC, Beura LK, Lucas PJ, Artis D, Wherry EJ, Hogquist K, Vezys V, Masopust D. Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues. *Journal of immunology*. 2012; 188(10):4866–4875. doi:10.4049/jimmunol.1200402.
107. Laidlaw BJ, Zhang N, Marshall HD, Staron MM, Guan T, Hu Y, Cauley LS, Craft J, Kaech SM. CD4(+) T Cell Help Guides Formation of CD103(+) Lung-Resident Memory CD8(+) T Cells during Influenza Viral Infection. *Immunity*. 2014; 41(4):633–645. doi:10.1016/j.immuni.2014.09.007. [PubMed: 25308332]
108. Ariotti S, Beltman JB, Chodaczek G, Hoekstra ME, van Beek AE, Gomez-Eerland R, Ritsma L, van Rheeën J, Maree AF, Zal T, de Boer RJ, Haanen JB, Schumacher TN. Tissue-resident memory CD8+ T cells continuously patrol skin epithelia to quickly recognize local antigen. *Proceedings of the National Academy of Sciences of the United States of America*. 2012; 109(48):19739–19744. doi:10.1073/pnas.1208927109. [PubMed: 23150545]
109. Mackay LK, Rahimpour A, Ma JZ, Collins N, Stock AT, Hafon ML, Vega-Ramos J, Lauzurica P, Mueller SN, Stefanovic T, Tschärke DC, Heath WR, Inouye M, Carbone FR, Gebhardt T. The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. *Nature immunology*. 2013; 14(12):1294–1301. doi:10.1038/ni.2744. [PubMed: 24162776]
110. Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS. Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity. *Nature*. 2012; 483(7388):227–231. doi:10.1038/nature10851. [PubMed: 22388819]
111. Schenkel JM, Fraser KA, Beura LK, Pauken KE, Vezys V, Masopust D. T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. *Science*. 2014; 346(6205):98–101. doi:10.1126/science.1254536. [PubMed: 25170049]
112. Sheridan BS, Pham QM, Lee YT, Cauley LS, Puddington L, Lefrançois L. Oral infection drives a distinct population of intestinal resident memory CD8(+) T cells with enhanced protective function. *Immunity*. 2014; 40(5):747–757. doi:10.1016/j.immuni.2014.03.007. [PubMed: 24792910]
113. Cepek KL, Shaw SK, Parker CM, Russell GJ, Morrow JS, Rimm DL, Brenner MB. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. *Nature*. 1994; 372(6502):190–193. doi:10.1038/372190a0. [PubMed: 7969453]
114. Skon CN, Lee JY, Anderson KG, Masopust D, Hogquist KA, Jameson SC. Transcriptional downregulation of S1pr1 is required for the establishment of resident memory CD8+ T cells. *Nature immunology*. 2013; 14(12):1285–1293. doi:10.1038/ni.2745. [PubMed: 24162775]
115. Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, Mueller SN, Heath WR, Carbone FR, Gebhardt T. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. *Proceedings of the National Academy of Sciences of the United States of America*. 2012; 109(18):7037–7042. doi:10.1073/pnas.1202288109. [PubMed: 22509047]
116. Zhang N, Bevan MJ. Transforming growth factor-beta signaling controls the formation and maintenance of gut-resident memory T cells by regulating migration and retention. *Immunity*. 2013; 39(4):687–696. doi:10.1016/j.immuni.2013.08.019. [PubMed: 24076049]
117. Vander Lugt B, Tubo NJ, Nizza ST, Boes M, Malissen B, Fuhlbrigge RC, Kupper TS, Campbell JJ. CCR7 plays no appreciable role in trafficking of central memory CD4 T cells to lymph nodes. *Journal of immunology*. 2013; 191(6):3119–3127. doi:10.4049/jimmunol.1200938.

Figure 1. Extravasation of naïve CD8⁺ T cells across High Endothelial Venules

The initial interaction between a naïve CD8⁺ T cells and HEVs occurs when L-selectin (CD62L) on the T cell binds to peripheral node addressins (PNAd) on the endothelium. The subsequent rolling that occurs due to these interactions allows the chemokine CCL21 to stimulate CCR7-mediated firm adhesion of LFA-1 to ICAM on the HEV. The naïve CD8⁺ T cells will then scan the HEV before finally transmigrating through the endothelium and entering the lymph node.

Figure 2. Examples of 6-sulfo-sialyl-Lewis X motifs on different glycans

(A) Symbolic representation of monosachharides found in O- and N-linked glycans. (B) Symbolic representation of the 6-sulfo-sialyl-Lewis X carbohydrate motif. (C) core 1 O-glycans, (D) core 2 O-glycans, and (E) N-glycans can all bear 6-sulfo-sialyl-Lewis X. This carbohydrate motif on sialomucins such as CD34 serves as the ligand for CD62L. Expression of 6-sulfo-sialyl-Lewis X on core 1 O-glycans (as shown in C) is also used to define HEVs *in vivo* by reacting with the MECA-79 antibody.

Figure 3. Memory CD8⁺ T cells express P- and E-selectin ligands in response to inflammation
 Most memory CD8⁺ T cells do not express core 2 O-glycans or bind to P- or E-selectin during homeostatic, steady-state conditions (left). However, in response to inflammatory IL-15, memory CD8⁺ T cells will synthesize core 2 O-glycans in a TCR-independent manner. The newly synthesized core 2 O-glycans on proteins such as PSGL-1 serve as ligands for P- and E-selectin and will subsequently attract these memory CD8⁺ T cells to inflamed tissues.

Figure 4. Differentiation of Tissue Resident Memory CD8⁺ T cells

Following infection, naïve CD8⁺ T cells become activated in draining lymph nodes by antigen, co-stimulation, and inflammatory cytokines, which drives their conversion into effector CD8⁺ T cells. These activated CD8⁺ T cells will then enter the efferent lymph and return to the circulation via the thoracic duct. After homing into tissues, effector CD8⁺ T cells will subsequently differentiate into resident memory CD8⁺ T cells in response to TGF-β. IL-33 and TNFα may also contribute to the establishment of tissue-resident memory CD8⁺ T cell populations.